This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Fred Khosravi and AccessClosure (C)
Hamermesh, Richard G.; Barley, LaurenCase HBS-814074-EEntrepreneurshipOn September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the company. The future looked bright for AccessClosure as 2013 drew to a close. The company expected 2014 revenues of more than $100 million with a gross margin of greater than 70%. It wa...Starting at €5.74
-
Whose Money Is It Anyway (C)
Narayanan, V.G.; Hamermesh, Richard G.; Gordon, RachelCase HBS-810031-EAccounting and ControlThe case describes how the Brigham and Women's Physicians Organization and its corporate parent resolved the issue of how the disputed funds would be distributed and used.Starting at €5.74
-
Whose Money Is It Anyway (A), (B), and (C), Teaching Note
Hamermesh, Richard G.; Narayanan, V.G.; Gordon, RachelTeaching Note HBS-111128-EAccounting and ControlTeaching Note for 810-008, 810-013, and 810-031.Starting at €0.00
-
Companion Diagnostics: Uncertainties for Approval and Reimbursement
Hamermesh, Richard G.; Selby, Norman C; Andrews, PhillipCase HBS-813037-EEntrepreneurshipThe FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine; The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questione...Starting at €8.20
-
Framework for Risk Management
Froot, Kenneth A.; Scharfstein, David S.; Stein, Jeremy C.Article HBS-94604-EStrategyIn recent years, managers have become aware of how their companies can be buffeted by risks beyond their control. To insulate themselves from such risks, many companies are turning to the derivatives markets, taking advantage of instruments like forwards, futures, options, and swaps. Although heavily involved in risk management, most companies do not have clear goals underlying their hedging programs. Without such goals, using derivatives can be ...Starting at €8.20
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Case HBS-302S36Knowledge and CommunicationDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Starting at €8.20
-
Bloodbuy
Hamermesh, Richard G.; Norris, MichaelCase HBS-815114-EEntrepreneurshipIn 2015, Chris Godfrey, founder and CEO of Bloodbuy has to consider the best path to growth for his young company that is attempting to disrupt the blood donation industry.Starting at €8.20
-
Amylin Pharmaceuticals B
Hamermesh, Richard G.; Knoop, Carin-IsabelCase HBS-813091-EEntrepreneurshipSupplement for case 809011Starting at €8.20
-
Novasys Medical
Hamermesh, Richard G.; Barley, LaurenCase HBS-810027-EEntrepreneurshipNovasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the product for reimbursement. The case deals with the company's struggle to obtain a reimbursement code.Starting at €8.20
-
Impact Investing for Cancer
Hamermesh, Richard G.; Preble, MatthewCase HBS-818068-EStrategyStarting at €8.20